Biocon Biologics has one of the deepest portfolios of biosimilars in the industry. Our long-term investments in R&D have yielded several molecules in oncology, of which three have already been commercialized in markets globally.

Pegfilgrastim

Approved in ~80 countries, including the U.S., EU countries, UK, Canada, Australia, NZ, many Emerging Market (EM) countries

Commercialized in the U.S., EU countries, Canada, Australia, some EM countries

Trastuzumab

Approved in 100+ countries, including the U.S., EU countries, UK, Canada, Australia, NZ & many EM countries

Commercialized in the U.S., EU countries, Australia, Canada, India, Brazil, Argentina, Turkey, Indonesia etc.

Bevacizumab

Approved in ~70 countries, including EU countries, UK, Canada, Australia, NZ & many EM countries; Filed in the U.S.

Commercialized in EU countries, Australia, Canada, India, Malaysia

Denosumab

Pertuzumab